Adam C. Vandervoort Sells 53,806 Shares of Teladoc, Inc. (TDOC) Stock
Teladoc, Inc. (NYSE:TDOC) insider Adam C. Vandervoort sold 53,806 shares of Teladoc stock in a transaction on Monday, August 7th. The stock was sold at an average price of $30.92, for a total value of $1,663,681.52. Following the sale, the insider now owns 33,008 shares in the company, valued at $1,020,607.36. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.
Shares of Teladoc, Inc. (NYSE TDOC) traded down 2.14% during midday trading on Wednesday, reaching $31.95. The company had a trading volume of 989,826 shares. The company’s 50-day moving average is $34.27 and its 200-day moving average is $27.04. Teladoc, Inc. has a 1-year low of $14.00 and a 1-year high of $36.90. The stock’s market capitalization is $1.75 billion.
Teladoc (NYSE:TDOC) last posted its earnings results on Wednesday, August 2nd. The health services provider reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by $0.02. Teladoc had a negative net margin of 47.75% and a negative return on equity of 19.88%. The firm had revenue of $44.60 million during the quarter, compared to the consensus estimate of $44.39 million. During the same period in the prior year, the company posted ($0.38) EPS. The firm’s revenue was up 68.3% compared to the same quarter last year. On average, equities research analysts forecast that Teladoc, Inc. will post ($1.33) EPS for the current year.
COPYRIGHT VIOLATION WARNING: This report was originally published by Watch List News and is the property of of Watch List News. If you are reading this report on another site, it was illegally copied and republished in violation of international copyright and trademark legislation. The correct version of this report can be read at https://www.watchlistnews.com/adam-c-vandervoort-sells-53806-shares-of-teladoc-inc-tdoc-stock/1466397.html.
Hedge funds and other institutional investors have recently bought and sold shares of the company. FMR LLC increased its position in Teladoc by 163.5% in the first quarter. FMR LLC now owns 8,103,237 shares of the health services provider’s stock valued at $202,581,000 after buying an additional 5,028,237 shares during the period. JPMorgan Chase & Co. increased its position in Teladoc by 8,826.7% in the first quarter. JPMorgan Chase & Co. now owns 1,606,535 shares of the health services provider’s stock valued at $40,163,000 after buying an additional 1,588,538 shares during the period. Alliancebernstein L.P. increased its position in Teladoc by 211.1% in the first quarter. Alliancebernstein L.P. now owns 2,286,200 shares of the health services provider’s stock valued at $57,155,000 after buying an additional 1,551,315 shares during the period. Janus Capital Management LLC bought a new position in Teladoc during the first quarter valued at approximately $37,258,000. Finally, Eagle Asset Management Inc. bought a new position in Teladoc during the first quarter valued at approximately $32,598,000. 95.88% of the stock is currently owned by hedge funds and other institutional investors.
TDOC has been the topic of a number of recent analyst reports. Canaccord Genuity reiterated a “buy” rating and set a $34.00 target price on shares of Teladoc in a research note on Wednesday, May 24th. Robert W. Baird reiterated a “buy” rating and set a $28.00 target price on shares of Teladoc in a research note on Tuesday, May 9th. Chardan Capital lifted their target price on Teladoc from $28.00 to $30.00 and gave the stock a “buy” rating in a research note on Tuesday, May 9th. Piper Jaffray Companies reiterated a “buy” rating and set a $32.00 target price on shares of Teladoc in a research note on Friday, July 14th. Finally, TheStreet upgraded Teladoc from a “d” rating to a “c-” rating in a research note on Thursday, April 13th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and ten have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $35.55.
Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.
Receive News & Ratings for Teladoc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.